Rates and predictors of starting a triptan: Results from the American Migraine Prevalence and Prevention Study

Headache

Volumn 50, Issue 9, 2010, Pages 1440-1448

  Bigal, Marcelo E ^a,b   Buse, Dawn C ^b,c   Chen, Ya Ting ^d,f   Golden, Wendy ^d   Serrano, Daniel ^e   Chu, Min Kyung ^g   Lipton, Richard B ^b,c  

^a UG3CD 68   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c MONTEFIORE MEDICAL CENTER   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

^e VEDANTA RESEARCH   (United States)

^f Sacred Heart Hospital   (South Korea)

^g Sacred Heart Hospital ^*

Author keywords

adequacy of care; migraine treatment; triptan

Indexed keywords

TRIPTAN DERIVATIVE;

ADULT; AGE; ALLODYNIA; ARTICLE; DEPRESSION; DISABILITY SEVERITY; DRUG USE; FEMALE; HEALTH INSURANCE; HUMAN; INCOME; MAJOR CLINICAL STUDY; MALE; MIGRAINE; MORBIDITY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROPHYLAXIS; SKIN PAIN; UNITED STATES; UNIVARIATE ANALYSIS;

ADOLESCENT; ADULT; ANALGESICS, NON-NARCOTIC; DRUG UTILIZATION; DRUG UTILIZATION REVIEW; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MIGRAINE DISORDERS; PREDICTIVE VALUE OF TESTS; PREVALENCE; TRYPTAMINES; UNITED STATES; YOUNG ADULT;

EID: 77957723606     PISSN: 00178748     EISSN: 15264610     Source Type: Journal    
DOI: 10.1111/j.1526-4610.2010.01703.x     Document Type: Article

References (36)

1. Lipton RB, Amatniek JC, Ferrari MD, Gross M, Migraine. Identifying and removing barriers to care. Neurology. 1994 44 (6 Suppl 4 S63 S68.
2. Silberstein SD, Dodick D, Kesslick J. Removing barriers to appropriate migraine treatment: Formulary limitations and triptan package size. Headache. 2005 45 : 1250 1254.
3. Wenzel R, Dortch M, Cady R, Lofland JH, Diamond S. Migraine headache misconceptions: Barriers to effective care. Pharmacotherapy. 2004 24 : 638 648.
4. Linde M, Jonsson P, Hedenrud T. Influence of disease features on adherence to prophylactic migraine medication. Acta Neurol Scand. 2008 118 : 367 372.
5. Ivers H, McGrath PJ, Purdy RA, Hennigar AW, Campbell MA. Decision making in migraine patients taking sumatriptan: An exploratory study. Headache. 2000 40 : 129 136.
6. Bigal M, Krymchantowski AV, Lipton RB. Barriers to satisfactory migraine outcomes. What have we learned, Where do we stand? Headache. 2009 Jul 49 (7 1028 1041.
7. Lipton RB, Kolodner K, Bigal ME, et al. Validity and reliability of the Migraine-Treatment Optimization Questionnaire. Cephalalgia. 2009 29 : 751 759.
8. Pryse-Phillips WE, Dodick DW, Edmeads JG, et al. Guidelines for the diagnosis and management of migraine in clinical practice. Canadian Headache Society. CMAJ. 1997 156 : 1273 1287.
9. Silberstein SD. Practice parameter: Evidence-based guidelines for migraine headache (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2000 55 : 754 762.
10. Cady RK, Maizels M, Reeves DL, Levinson DM, Evans JK. Predictors of adherence to triptans: Factors of sustained vs lapsed users. Headache. 2009 49 : 386 394.
11. Katic BJ, Krause SJ, Tepper SJ, Hu HX, Bigal ME. Adherence to acute migraine medication: What does it mean, why does it matter? Headache. 2010 50 : 117 129.
12. Rains JC, Penzien DB, Lipchik GL. Behavioral facilitation of medical treatment for headache - part II: Theoretical models and behavioral strategies for improving adherence. Headache. 2006 46 : 1395 1403.
13. Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007 68 : 343 349.
14. Stewart WFRM, Bigal ME, Lipton RB. Lifetime migraine incidence. Results from the American Migraine Prevalence and Prevention study. Headache. 2005 46 : 52.
15. Lipton RB, Bigal ME, Ashina S, et al. Cutaneous allodynia in the migraine population. Ann Neurol. 2008 63 : 148 158.
16. Society. HCSotIH. The International Classification of Headache Disorders. 2nd Edition. Cephalalgia. 2004 24 (Suppl 1 1 149.
17. Lipton RB, Stewart WF, Simon D. Medical consultation for migraine: Results from the American Migraine Study. Headache. 1998 38 : 87 96.
18. Stewart WF, Lipton RB, Kolodner KB, Sawyer J, Lee C, Liberman JN. Validity of the Migraine Disability Assessment (MIDAS) score in comparison to a diary-based measure in a population sample of migraine sufferers. Pain. 2000 88 : 41 52.
19. Lipton RB, Stewart WF, Sawyer J, Edmeads JG. Clinical utility of an instrument assessing migraine disability: The Migraine Disability Assessment (MIDAS) questionnaire. Headache. 2001 41 : 854 861.
20. Spitzer RL, Williams JB, Kroenke K, Hornyak R, McMurray J. Validity and utility of the PRIME-MD patient health questionnaire in assessment of 3000 obstetric-gynecologic patients: The PRIME-MD Patient Health Questionnaire Obstetrics-Gynecology Study. Am J Obstet Gynecol. 2000 183 : 759 769.
21. Jakubowski M, Silberstein S, Ashkenazi A, Burstein R. Can allodynic migraine patients be identified interictally using a questionnaire? Neurology. 2005 65 : 1419 1422.
22. Silberstein SD. Clinical practice guidelines. Cephalalgia. 2005 25 : 765 766.
23. Solomon GD, Santanello N. Impact of migraine and migraine therapy on productivity and quality of life. Neurology. 2000 55 (9 Suppl 2 S29 S35.
24. Dowson A, Jagger S. The UK migraine patient survey: Quality of life and treatment. Curr Med Res Opin. 1999 15 : 241 253.
25. Garcia ML, Baos V, Lainez M, Pascual J, Lopez-Gil A. Responsiveness of migraine-ACT and MIDAS questionnaires for assessing migraine therapy. Headache. 2008 48 : 1349 1355.
26. Pascual J, Lainez MJ, Baos V, Garcia ML, Lopez-Gil A. Predictive model for the Migraine-ACT questionnaire in primary care. Curr Med Res Opin. 2007 23 : 3033 3039.
27. Hargreaves RJ. Pharmacology and potential mechanisms of action of rizatriptan. Cephalalgia. 2000 20 (Suppl 1 2 9.
28. Goadsby PJ, Hargreaves RJ. Mechanisms of action of serotonin 5-HT1B/D agonists: Insights into migraine pathophysiology using rizatriptan. Neurology. 2000 55 (9 Suppl 2 S8 14.
29. Golden WM, Bigal ME, Yu J, et al. Impact of cardiovascular disease and cardiovascular risk on the treatment of migraine. Am J Med. 2009 Submitted.
30. Celentano DD, Stewart WF, Lipton RB, Reed ML. Medication use and disability among migraineurs: A national probability sample survey. Headache. 1992 32 : 223 228.
31. Bigal ME, Lipton RB, Winner P, Reed ML, Diamond S, Stewart WF. Migraine in adolescents: Association with socioeconomic status and family history. Neurology. 2007 69 : 16 25.
32. Hu XH, Markson LE, Lipton RB, Stewart WF, Berger ML. Burden of migraine in the United States: Disability and economic costs. Arch Intern Med. 1999 159 : 813 818.
33. Lipton RB, Bigal ME, Stewart WF. Clinical trials of acute treatments for migraine including multiple attack studies of pain, disability, and health-related quality of life. Neurology. 2005 65 (12 Suppl 4 S50 S58.
34. Bigal ME, Lipton RB. Excessive acute migraine medication use and migraine progression. Neurology. 2008 71 : 1821 1828.
35. Katsarava Z, Schneeweiss S, Kurth T, et al. Incidence and predictors for chronicity of headache in patients with episodic migraine. Neurology. 2004 62 : 788 790.
36. Burstein R, Collins B, Jakubowski M. Defeating migraine pain with triptans: A race against the development of cutaneous allodynia. Ann Neurol. 2004 55 : 19 26.